Read more

January 22, 2021
5 min watch
Save

VIDEO: Study shows ‘curative potential’ in patients with relapsed refractory disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Jakub Svoboda, MD, of Penn Medicine, discussed data from the ZUMA-12 study presented at the ASH Annual Meeting and Exposition.

The ZUMA-12 trial examined the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.

“Thinking about using this potent and exciting therapy that can provide curative potential in patients with relapsed refractory disease, but in a population of patients that in theory have curative options in the frontline setting before any chemotherapy, is a provocative, exciting and interesting study,” Svoboda told Healio in a video interview.